Name in SEC filings: ENANTA PHARMACEUTICALS INC
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| EDP-978 | /data readout | Phase 1 | 2026 | 8-K · |
| zelicapavir | Topline/data readout | Stage not stated | 2027 | 8-K · |
| zelicapavir | Topline/data readout | Phase 2 | 2027 | 8-K · |
Source: ORION, orionbiotechai.com/company/ENTA, data as of Oct 18, 2026
https://www.orionbiotechai.com/company/ENTA
EDP-978 · Topline/data readout · 4Q 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readout4Q 2026
Stage: Phase 1SEC filing · “Phase 1”
Public float: $110,592,792 · as of · SEC filing
On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readout2027
Stage: Not stated
Public float: $110,592,792 · as of · SEC filing
LOTUS is designed to evaluate the efficacy, safety, and antiviral activity of zelicapavir, with topline data expected in 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Topline/data readout2027
Stage: Phase 2SEC filing · “Phase 2b”
Public float: $110,592,792 · as of · SEC filing
Topline Phase 2b data from RESOLVE is expected in 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| EDP-978Clinical results | 4Q 2026“On Track to Report Topline Data from a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Urticaria, in 4Q 2026” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| zelicapavirClinical results | 2027“LOTUS is designed to evaluate the efficacy, safety, and antiviral activity of zelicapavir, with topline data expected in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| zelicapavirClinical results | 2027“Topline Phase 2b data from RESOLVE is expected in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| zelicapavirClinical results | 2027“Enanta also announced plans to initiate a Phase 2b clinical trial of zelicapavir in pediatric patients with RSV, with topline data expected in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| zelicapavirClinical results | 2027“with topline data expected in 2027” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| zelicapavirClinical results | 2027“The Phase 2b portion of the trial will confirm the treatment effect with topline data expected in 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| zelicapavirClinical results | 2027“with data from the Phase 2b portion expected in 2027” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| EDP-978Clinical results | fourth quarter of 2026“We expect to report topline data from this trial in the fourth quarter of 2026.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| EDP-978Clinical results | fourth quarter of 2026“The Company expects to report topline data from the trial in the fourth quarter of 2026.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| EDP-978Clinical results | fourth quarter of 2026“with topline Phase 1 data expected in the fourth quarter of 2026.” Filed · 10-Q | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for ENTA. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See ENTA in the calendar · Review labels and methodology